News & Media

Aplantex crosses a key milestone with its transition from research mode to an initial operational phase

February 5, 2026

Aplantex continues its remarkable growth. Our innovative green biotechnology approach, providing a continuous and sustainable supply of high-demand molecules for the cosmetic, food, natural health, and pharmaceutical industries, has proven successful. We are therefore beginning the transition from a research-focused startup to a high-performing production-oriented organization, supported by targeted research to meet specific customer needs.

Today, we are turning our innovation into concrete, sustainable solutions for our partners

The planning for the construction of the Canadian pilot plant is complete. Focused on our modular and proprietary industrial platform, the plant will allow us to produce locally, in a tightly controlled indoor environment protected from seasonal cycles, an abundant biomass from which the valuable molecules sought by leading customers are extracted. To that end, negotiations for the initial commercial agreements that began in recent months are in the final stages, and we are now finalizing the financial structure through our Series A initiative, which aims to support our robust growth.

Finally, the team welcomes new impactful players on the board of directors, the advisory board, and within the operations team and research lab. With enthusiasm, determination, and confidence, the entire team is working hard to achieve the ambitious goals it has set for the upcoming year.


Other articles of interestView all

April 9, 2026

Our progression at a glance

To know more
April 2, 2026

Our business opportunities are taking shape and multiplying

To know more
March 25, 2026

Aplantex and the City of Montreal in the spotlight in Paris

To know more